Sigyn Therapeutics Relocates HQ to Beverly Hills

Ticker: SIGY · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1642159

Sigyn Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySigyn Therapeutics, Inc. (SIGY)
Form Type8-K
Filed DateJan 30, 2024
Risk Levellow
Pages2
Reading Time3 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, administrative-change

TL;DR

**Sigyn Therapeutics moved its HQ to Beverly Hills, signaling potential strategic changes.**

AI Summary

On January 30, 2024, Sigyn Therapeutics, Inc. filed an 8-K to report a change in its principal executive offices from 2468 Historic Decatur Road, Suite 140, San Diego, CA 92106 to 9190 W Olympic Blvd # 263, Beverly Hills, CA 90212. This move signifies a potential shift in operational strategy or a desire for a more prominent location, which could impact investor perception of the company's stability and future growth prospects.

Why It Matters

A change in headquarters can signal a strategic shift, cost-cutting measures, or expansion plans, all of which can influence investor confidence and the company's operational efficiency.

Risk Assessment

Risk Level: low — The filing primarily reports an administrative change of address, which typically carries a low direct risk to investors.

Analyst Insight

Investors should monitor future filings for any strategic announcements or financial impacts related to the change in headquarters, as this administrative change itself doesn't provide direct financial insight.

Key Numbers

  • 619-368-2000 — New Business Phone Number (The new contact number for Sigyn Therapeutics, Inc. after the relocation.)

Key Players & Entities

  • Sigyn Therapeutics, Inc. (company) — the registrant changing its principal executive offices
  • January 30, 2024 (date) — date of earliest event reported and filing date
  • 9190 W Olympic Blvd # 263, Beverly Hills, CA 90212 (location) — new principal executive offices address
  • 2468 Historic Decatur Road, Suite 140, San Diego, CA 92106 (location) — prior principal executive offices address
  • 619-368-2000 (dollar_amount) — new business phone number

Forward-Looking Statements

  • The relocation to Beverly Hills may lead to increased operational costs for Sigyn Therapeutics. (Sigyn Therapeutics, Inc.) — medium confidence, target: 2024-12-31

FAQ

What was the previous address of Sigyn Therapeutics, Inc.'s principal executive offices?

The previous address of Sigyn Therapeutics, Inc.'s principal executive offices was 2468 Historic Decatur Road, Suite 140, San Diego, CA 92106.

What is the new address for Sigyn Therapeutics, Inc.'s principal executive offices?

The new address for Sigyn Therapeutics, Inc.'s principal executive offices is 9190 W Olympic Blvd # 263, Beverly Hills, CA 90212.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on January 30, 2024.

What is the new telephone number for Sigyn Therapeutics, Inc.?

The new telephone number for Sigyn Therapeutics, Inc. is 619-368-2000.

Under which item information categories was this 8-K filed?

This 8-K was filed under 'Material Modifications to Rights of Security Holders', 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year', and 'Financial Statements and Exhibits'.

Filing Stats: 715 words · 3 min read · ~2 pages · Grade level 11 · Accepted 2024-01-30 16:23:47

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGYN THERAPEUTICS, INC. Date: January 30, 2024 By: /s/ James A. Joyce James A. Joyce, Chairman and CEO

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.